HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression
Advanced Science · 2024
DOI: 10.1002/advs.202400920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Woo Seon Choi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Stem Cell Immunomodulation Research Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, R…. Hauptthemen laut MEDLINE: Disease Progression, Killer Cells, Natural, Melanoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT (MSIT) of the government of Korea, Korean government (MSIT), grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare.
Abstract (Originalsprache)
Distant metastasis, the leading cause of cancer death, is efficiently kept in check by immune surveillance. Studies have uncovered peripheral natural killer (NK) cells as key antimetastatic effectors and their dysregulation during metastasis. However, the molecular mechanism governing NK cell dysfunction links to metastasis remains elusive. Herein, MAP4K1 encoding HPK1 is aberrantly overexpressed in dysfunctional NK cells in the periphery and the metastatic site. Conditional HPK1 overexpression in NK cells suffices to exacerbate melanoma lung metastasis but not primary tumor growth. Conversely, MAP4K1 ‐deficient mice are resistant to metastasis and further protected by combined immune‐checkpoint inhibitors. Mechanistically, HPK1 restrains NK cell cytotoxicity and expansion via activating receptors. Likewise, HPK1 limits human NK cell activation and associates with melanoma NK cell dysfunction couples to TGF‐β1 and patient response to immune checkpoint therapy. Thus, HPK1 is an intracellular checkpoint controlling NK‐target cell responses, which is dysregulated and hijacked by tumors during metastatic progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Stem Cell Immunomodulation Research Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
- Department of Dermatology, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
- Department of Cell and Genetic Engineering, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
- Department of Pathology, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
ORCID-Profile: Hun Sik Kim
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT (MSIT) of the government of Korea
- Korean government (MSIT), grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare
Zitieren
APA
Choi, W. S., Kwon, H. J., Yi, E., Lee, H., Kim, J. M., Park, H. J., Choi, E. J., Choi, M. E., Sung, Y. H., Won, C. H., Sung, C. O., & Kim, H. S. (2024). HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression. Advanced Science. https://doi.org/10.1002/advs.202400920
Vancouver
Choi WS, Kwon HJ, Yi E, Lee H, Kim JM, Park HJ, et al. HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression. Advanced Science. 2024. doi:10.1002/advs.202400920
BibTeX
@article{Choi2024,
author = {Choi, Woo Seon and Kwon, Hyung-Joon and Yi, Eunbi and Lee, Haeun and Kim, Jung Min and Park, Hyo Jin and Choi, Eun Ji and Choi, Myoung Eun and Sung, Young Hoon and Won, Chong Hyun and Sung, Chang Ohk and Kim, Hun Sik},
title = {HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202400920}
}
EUVIMED